Biodesix, Inc. (NASDAQ:BDSX) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 775.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 360,200 shares of the company’s stock after acquiring an additional 319,043 shares during the quarter. Renaissance Technologies LLC owned about 0.25% of Biodesix worth $551,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Barclays PLC increased its position in shares of Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the last quarter. HighTower Advisors LLC boosted its stake in Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after buying an additional 22,500 shares during the period. Stephens Inc. AR acquired a new stake in shares of Biodesix during the fourth quarter valued at about $303,000. Geode Capital Management LLC raised its stake in shares of Biodesix by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after acquiring an additional 22,623 shares during the period. Finally, Perkins Capital Management Inc. lifted its holdings in shares of Biodesix by 46.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock worth $1,622,000 after acquiring an additional 335,429 shares during the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on BDSX. William Blair reiterated an “outperform” rating on shares of Biodesix in a report on Tuesday, March 4th. Canaccord Genuity Group cut their price objective on Biodesix from $3.50 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Biodesix currently has an average rating of “Buy” and a consensus target price of $2.83.

Biodesix Price Performance

Biodesix stock opened at $0.52 on Friday. The company’s 50 day moving average is $0.66 and its two-hundred day moving average is $1.07. The firm has a market cap of $75.86 million, a PE ratio of -1.33 and a beta of 1.17. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 52-week low of $0.45 and a 52-week high of $2.04.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The firm had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. On average, research analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 128,702 shares of company stock worth $118,406 in the last 90 days. Corporate insiders own 69.20% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.